XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Revenue $ 6,740.1 $ 5,499.4 $ 13,545.7 $ 11,359.2
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,704.2 3,144.8 7,645.5 6,473.6
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,035.9 2,354.6 5,900.2 4,885.6
Diabetes        
Disaggregation of Revenue [Line Items]        
Revenue 3,175.5 2,779.0 6,286.6 5,747.9
Diabetes | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 2,079.8 1,873.3 4,141.0 3,864.5
Diabetes | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,095.7 905.7 2,145.5 1,883.4
Trulicity®        
Disaggregation of Revenue [Line Items]        
Revenue 1,535.6 1,229.8 2,988.1 2,459.1
Trulicity® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,147.6 952.5 2,264.3 1,882.0
Trulicity® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 388.0 277.2 723.7 577.1
Humalog®        
Disaggregation of Revenue [Line Items]        
Revenue 607.6 555.1 1,224.6 1,250.8
Humalog® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 329.1 281.7 661.7 680.3
Humalog® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 278.6 273.3 562.9 570.5
Humulin®        
Disaggregation of Revenue [Line Items]        
Revenue 315.3 313.6 637.0 629.3
Humulin® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 221.1 214.3 440.1 428.4
Humulin® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 94.3 99.3 196.9 200.8
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 356.5 262.0 668.5 529.5
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 194.4 145.1 345.6 289.7
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 162.1 116.9 322.9 239.8
Basaglar®        
Disaggregation of Revenue [Line Items]        
Revenue 210.7 290.4 457.3 594.1
Basaglar® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 133.4 229.7 308.6 460.1
Basaglar® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 77.3 60.7 148.7 134.0
Other Diabetes        
Disaggregation of Revenue [Line Items]        
Revenue 149.8 128.1 311.1 285.1
Other Diabetes | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 54.2 50.0 120.7 124.0
Other Diabetes | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 95.4 78.3 190.4 161.2
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 1,554.0 1,268.6 2,926.3 2,470.1
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 828.3 682.7 1,470.8 1,340.6
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 725.7 585.9 1,455.4 1,129.5
Alimta®        
Disaggregation of Revenue [Line Items]        
Revenue 610.6 539.1 1,169.6 1,099.2
Alimta® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 353.5 317.2 614.6 641.5
Alimta® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 257.1 221.9 554.9 457.7
Verzenio®        
Disaggregation of Revenue [Line Items]        
Revenue 341.3 208.6 610.3 396.7
Verzenio® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 209.7 141.7 382.5 271.1
Verzenio® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 131.6 66.9 227.8 125.6
Cyramza®        
Disaggregation of Revenue [Line Items]        
Revenue 268.7 256.7 509.2 495.7
Cyramza® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 101.4 94.1 181.5 183.2
Cyramza® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 167.3 162.7 327.7 312.5
Erbitux®        
Disaggregation of Revenue [Line Items]        
Revenue 147.0 129.5 269.4 260.3
Erbitux® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 135.8 115.8 243.7 233.7
Erbitux® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 11.2 13.7 25.7 26.7
Tyvyt®        
Disaggregation of Revenue [Line Items]        
Revenue 105.0 64.1 214.6 121.5
Tyvyt® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 0.0 0.0 0.0 0.0
Tyvyt® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 105.0 64.1 214.6 121.5
Other Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 81.4 70.6 153.2 96.7
Other Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 27.9 13.9 48.5 11.1
Other Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 53.5 56.6 104.7 85.5
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 785.4 548.3 1,399.3 1,134.1
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 422.4 310.5 707.1 651.9
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 363.1 237.8 692.2 482.2
Taltz®        
Disaggregation of Revenue [Line Items]        
Revenue 569.1 395.2 972.4 838.7
Taltz® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 399.8 289.2 649.4 616.7
Taltz® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 169.3 106.0 322.9 222.0
Olumiant®        
Disaggregation of Revenue [Line Items]        
Revenue 208.4 145.0 402.2 284.7
Olumiant® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 17.8 13.2 42.5 24.5
Olumiant® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 190.6 131.8 359.7 260.2
Other Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 7.9 8.1 24.7 10.7
Other Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 4.8 8.1 15.2 10.7
Other Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3.2 0.0 9.6 0.0
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 512.2 422.5 977.6 886.0
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 166.7 104.0 308.4 214.2
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 345.5 318.5 669.2 671.7
Cymbalta®        
Disaggregation of Revenue [Line Items]        
Revenue 175.6 179.9 352.3 390.3
Cymbalta® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 12.4 7.7 23.3 19.3
Cymbalta® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 163.3 172.1 328.9 370.9
Emgality®        
Disaggregation of Revenue [Line Items]        
Revenue 156.3 87.4 275.7 161.5
Emgality® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 112.1 80.6 213.6 147.9
Emgality® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 44.2 6.8 62.2 13.6
Zyprexa®        
Disaggregation of Revenue [Line Items]        
Revenue 95.4 96.6 191.1 195.0
Zyprexa® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 8.4 9.1 15.3 20.3
Zyprexa® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 86.9 87.5 175.8 174.7
Other Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 84.9 58.6 158.5 139.2
Other Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 33.8 6.6 56.2 26.7
Other Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 51.1 52.1 102.3 112.5
Other        
Disaggregation of Revenue [Line Items]        
Revenue 712.9 481.0 1,955.9 1,121.1
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 207.0 174.4 1,018.1 402.4
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 506.0 306.7 937.8 718.7
COVID-19 Antibodies        
Disaggregation of Revenue [Line Items]        
Revenue 148.9 0.0 959.1 0.0
COVID-19 Antibodies | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 83.4 0.0 734.0 0.0
COVID-19 Antibodies | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 65.7 0.0 225.1 0.0
Forteo®        
Disaggregation of Revenue [Line Items]        
Revenue 218.4 252.7 416.9 525.0
Forteo® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 122.8 119.6 220.5 242.2
Forteo® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 95.6 133.0 196.4 282.9
Cialis®        
Disaggregation of Revenue [Line Items]        
Revenue 281.0 130.7 407.8 323.8
Cialis® | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue (5.2) 23.4 3.4 49.5
Cialis® | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 286.3 107.3 404.4 274.3
Other        
Disaggregation of Revenue [Line Items]        
Revenue 64.6 97.6 172.1 272.3
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 6.0 31.4 60.2 110.7
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 58.4 $ 66.4 $ 111.9 $ 161.5